نتائج البحث - "Н. Т. Ватутин"

المصدر: The Russian Archives of Internal Medicine; Том 12, № 1 (2022); 62-71 ; Архивъ внутренней медицины; Том 12, № 1 (2022); 62-71 ; 2411-6564 ; 2226-6704

مصطلحات موضوعية: летальность, decompensation, full yogic breathing, dyspnea, quality of life, diuretics, duration of hospitalization, mortality, декомпенсация, полное йоговское дыхание, одышка, качество жизни, диуретики, сроки госпитализации

وصف الملف: application/pdf

العلاقة: https://www.medarhive.ru/jour/article/view/1377/1090Test; https://www.medarhive.ru/jour/article/view/1377/1097Test; Chaudhry S-P., Stewart G.C. Advanced Heart Failure: Prevalence, Natural History, and Prognosis. Heart Fail Clin. 2016; 12(3): 323-333. doi:10.1016/j.hfc.2016.03.001; Lalande S., Cross T.J., Keller-Ross M.L. et al. Exercise Intolerance in Heart Failure: Central Role for the Pulmonary System. Exercise and Sport Sciences Reviews. 2020; 48(1): 11-19. doi:10.1249/JES.0000000000000208; Nakagawa N.K., Diz M.A., Kawauchi T.S. et al. Risk Factors for Inspiratory Muscle Weakness in Chronic Heart Failure. Respir Care. 2020; 65(4): 507-516. doi:10.4187/respcare.06766; Laoutaris I.D. The “aerobic/resistance/inspiratory muscle training hypothesis in heart failure.” Eur J Prev Cardiol. 2018; 25(12): 1257-1262. doi:10.1177/2047487318776097; Argilés J.M., Busquets S., Stemmler B. et al. Cachexia and sarcopenia: mechanisms and potential targets for intervention. Curr Opin Pharmacol. 2015; 22: 100-106. doi:10.1016/j.coph.2015.04.003; Dos Santos M.R., Saitoh M., Ebner N. et al. Sarcopenia and Endothelial Function in Patients With Chronic Heart Failure: Results From the Studies Investigating Comorbidities Aggravating Heart Failure (SICA-HF). J Am Med Dir Assoc. 2017; 18(3): 240-245. doi:10.1016/j.jamda.2016.09.006; Okwose N.C., Avery L., O’Brien N. et al. Acceptability, Feasibility and Preliminary Evaluation of a Novel, Personalised, Home-Based Physical Activity Intervention for Chronic Heart Failure (Active-at-Home-HF): a Pilot Study. Sports Medicine — Open. 2019; 5(1): 45. doi:10.1186/s40798-019-0216-x; Cattadori G., Segurini C., Picozzi A. et al. Exercise and heart failure: an update. ESC Heart Fail. 2018; 5(2): 222-232. doi:10.1002/ehf2.12225; Oz Alkan H., Uysal H., Enç N. et al. Influence of Breathing Exercise Education Applied on Patients with Heart Failure on Dyspnoea and Quality of Sleep: A Randomized Controlled Study. International Journal of Medical Research & Health Sciences. 2017; 6(9): 107-113; Belardinelli R., Georgiou D., Cianci G. et al. Randomized, controlled trial of long-term moderate exercise training in chronic heart failure: effects on functional capacity, quality of life, and clinical outcome. Circulation. 1999; 99(9): 1173-1182. doi:10.1161/01.cir.99.9.1173; Арутюнов Г.П., Колесникова Е.А., Беграмбекова Ю.Л. и др. Рекомендации по назначению физических тренировок пациентам с хронической сердечной недостаточностью. Журнал Сердечная Недостаточность. 2017; 18(1): 41-66. doi:10.18087/rhfj.2017.1.2339; Троицкий М.С., Федоров С.Ю., Борисова О.Н. и др. Инновации в тренировке дыхательной мускулатуры (литературный обзор). Вестник Новых Медицинских Технологий. Электронное Издание. 2015; 2: 3-7. doi:10.12737/11911; Udupa K., Madanmohan N., Bhavanani A.B. et al. Effect of pranayam training on cardiac function in normal young volunteers. Indian J Physiol Pharmacol. 2003; 47(1): 27-33.; Ponikowski P., Voors A.A., Anker S.D. et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016; 18(8): 891-975. doi:10.1002/ejhf.592; Saitoh M., Ishida J., Doehner W. et al. Sarcopenia, cachexia, and muscle performance in heart failure: Review update 2016. Int J Cardiol. 2017; 238: 5-11. doi:10.1016/j.ijcard.2017.03.155; Giallauria F., Piccioli L., Vitale G. et al. Exercise training in patients with chronic heart failure: A new challenge for Cardiac Rehabilitation Community. Monaldi Arch Chest Dis. 2018; 88(3): 987. doi:10.4081/monaldi.2018.987; Ribeiro J.P., Chiappa G.R., Callegaro C.C. The contribution of inspiratory muscles function to exercise limitation in heart failure: pathophysiological mechanisms. Rev Bras Fisioter. 2012; 16(4): 261-267. doi:10.1590/s1413-35552012005000034; Boushel R. Muscle metaboreflex control of the circulation during exercise. Acta Physiol (Oxf). 2010; 199(4): 367-383. doi:10.1111/j.1748-1716.2010.02133.x; Беграмбекова Ю.Л., Каранадзе Н.А., Орлова Я.А. Нарушения системы дыхания при хронической сердечной недостаточности. Кардиология. 2019; 59(2S): 15-24. doi:10.18087/cardio.2626; Meyer F.J., Borst M.M., Zugck C. et al. Respiratory muscle dysfunction in congestive heart failure: clinical correlation and prognostic significance. Circulation. 2001; 103(17): 2153-2158. doi:10.1161/01.cir.103.17.2153; Winkelmann E.R., Chiappa G.R., Camila O.C. Lima. et al. Addition of inspiratory muscle training to aerobic training improves cardiorespiratory responses to exercise in patients with heart failure and inspiratory muscle weakness. Am Heart J. 2009; 158(5): 768.e1-7. doi:10.1016/j.ahj.2009.09.005; Stein R., Chiappa G.R., Güths H. et al. Inspiratory muscle training improves oxygen uptake efficiency slope in patients with chronic heart failure. J Cardiopulm Rehabil Prev. 2009; 29(6): 392-395. doi:10.1097/HCR.0b013e3181b4cc41; Laoutaris I.D., Adamopoulos S., Manginas A. et al. Benefits of combined aerobic/resistance/inspiratory training in patients with chronic heart failure. A complete exercise model? A prospective randomised study. Int J Cardiol. 2013; 167(5): 1967-1972. doi:10.1016/j.ijcard.2012.05.019; Montemezzo D., Fregonezi G.A., Pereira D.A. et al. Influence of inspiratory muscle weakness on inspiratory muscle training responses in chronic heart failure patients: a systematic review and meta-analysis. Archives of Physical Medicine and Rehabilitation. 2014; 95(7): 1398-1407. doi:10.1016/j.apmr.2014.02.022; Passino C., Giannoni A., Milli M. et al. Recent knowledges on chemosensitivity to hypoxia and hypercapnia in cardiovascular disease. Recenti Prog Med. 2010; 101(7-8): 308-313.; Novaes M.M., Palhano-Fontes F., Onias H. et al. Effects of Yoga Respiratory Practice (Bhastrika pranayama) on Anxiety, Affect, and Brain Functional Connectivity and Activity: A Randomized Controlled Trial. Front Psychiatry. 2020; 11: 467. doi:10.3389/fpsyt.2020.00467; Shinba T., Inoue T., Matsui T. et al. Changes in Heart Rate Variability after Yoga are Dependent on Heart Rate Variability at Baseline and during Yoga: A Study Showing Autonomic Normalization Effect in Yoga-Naïve and Experienced Subjects. Int J Yo ga. 2020; 13(2): 160-167. doi:10.4103/ijoy.IJOY_39_19; Garcia A.J., Koschnitzky J.E., Dashevskiy T. et al. Cardiorespiratory Coupling in Health and Disease. Auton Neurosci. 2013; 175(0): 26-37. doi:10.1016/j.autneu.2013.02.006; Покровский В.М., Коротько Г.Ф. Физиология человека. 2003; 656 с. [Электронный ресурс]. URL: https://www.booksmed.com/fiziologiya/565-fiziologiya-cheloveka-pokrovskij-uchebnik.htmlTest. (дата обращения: 12.06.2020).; Smart N.A., Giallauria F., Dieberg G. Efficacy of inspiratory muscle training in chronic heart failure patients: a systematic review and meta-analysis. Int J Cardiol. 2013; 167(4): 1502-1507. doi:10.1016/j.ijcard.2012.04.029; https://www.medarhive.ru/jour/article/view/1377Test

الإتاحة: https://doi.org/10.20514/2226-6704-2022-12-1-62-71Test
https://doi.org/10.1016/j.hfc.2016.03.001Test
https://doi.org/10.1249/JES.0000000000000208Test
https://doi.org/10.4187/respcare.06766Test
https://doi.org/10.1177/2047487318776097Test
https://doi.org/10.1016/j.coph.2015.04.003Test
https://doi.org/10.1016/j.jamda.2016.09.006Test
https://doi.org/10.1186/s40798-019-0216-xTest
https://doi.org/10.1002/ehf2.12225Test
https://doi.org/10.1161/01.cir.99.9.1173Test

View record in BASE

6

دورية أكاديمية

Position of Patients with Mid-Range Ejection Fraction in the General Chronic Heart Failure Population ; Место пациентов с промежуточной фракцией выброса левого желудочка в общей популяции больных хронической сердечной недостаточностью

المؤلفون: N. T. Vatutin, A. N. Shevelok, V. V. Venzheha, Н. Т. Ватутин, А. Н. Шевелёк, В. В. Венжега

المصدر: The Russian Archives of Internal Medicine; Том 11, № 2 (2021); 111-121 ; Архивъ внутренней медицины; Том 11, № 2 (2021); 111-121 ; 2411-6564 ; 2226-6704

مصطلحات موضوعية: принципы лечения, left ventricle, mid-ran ge ejection fraction, transition phenotypes, prognosis, guidelines of treatment, левый желудочек, промежуточная фракция выброса, динамические фенотипы, прогноз

وصف الملف: application/pdf

العلاقة: https://www.medarhive.ru/jour/article/view/1171/992Test; https://www.medarhive.ru/jour/article/view/1171/1005Test; Гарганеева А.А., Бауэр В.А., Борель К.Н. ПанедемияXXI века: хроническая сердечная недостаточность — бремя современного общества. Эпидемиологические аспекты (обзор литературы). Сибирский медицинский журнал. 2014; 29 (3):8-12. ISSN: 2073-8552.; Longjian L. Epidemiology of heart failure and scope of the problem. CardiologyClinics. 2014; 32:1–8. DOI:10.1016/j.ccl.2013.09.009; Шляхто Е.В. Кардиология. Национальное руководство. Краткое издание / под ред. Е.В. Шляхто. — 2-е изд., перераб. и доп. — М.: ГЭОТАР-Медиа. 2018; 691-711. ISBN 978-5-9704-5397-1.; Ситникова М.Ю. Хроническая сердечная недостаточность: эпидемиология и перспективы планирования. Сердечная недостаточность. 2012; 6(74):372–376. ISSN: 1728-4651.; Lуpez_Sendуn J. The heart failure epidemic. Medicographia. 2011; 33:363–369. ISSN 0243-3397.; Ponikowski P, Voors A.A., Anker S.D.et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975. DOI:10.1093/eurheartj/ehw128.; Bayés-Genís A., Núñez J., Lupón J. et al. Heart Failure with mid-range ejection fraction: a transition phenotype? European journal of Heart Failure. 2017:1-3. DOI:10.1002/ejhf.977.; Lam C.S., Solomon S.D. The middle child in heart failure: heart failure with mid-rangeejection fraction (40–50 %). Eur J Heart Fail.2014;16:1049–1055. DOI:10.1002/ejhf.159.; Dickstein K., Cohen-Solal A., Filippatos G. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. European Heart Journal. 2008; 29(19), 2388-2442. DOI:10.1093/eurheartj/ehn309.; McMurray J.J., Adamopoulos S., Anker S.D. et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33(14):1787-847. DOI:10.1093/eurheartj/ehs104. Epub 2012 May 19.; Lam C.S.P., Teng T.HK. Understanding Heart Failure With Mid-Range Ejection Fraction. JACC: Heart Failure 2016; 4(6):1-4. DOI:10.1016/j.jchf.2016.03.025.; Andronic A.A., Mihaila S., Cinteza M. et al. Heart Failure with Mid- Range Ejection Fraction — a New Category of Heart Failure or Still a Gray Zone. MAEDICA — a Journal of Clinical Medicine. 2016; 11(4):320-324. PMID: 28828050.; Lauritsen J., Gustafsson F., Jawdat A. et al. Characteristics and longterm prognosis of patients with heart failure and mid-range ejection fraction compared with reduced and preserved ejection fraction: a systematic review and meta-analysis. ESC Heart Failure. 2018: 1-10. DOI:10.1002/ehf2.12283.; Jeffrey J.H., Boback Z., Gregg C.F. et al. Heart Failure With Mid- Range (Borderline) Ejection Fraction Clinical Implications and Future Directions. JACC: Heart Failure. 2017; 5(11): 763-771. DOI:10.1016/j.jchf.2017.06.013; Nauta J.F., Hummel Y.M., Melle J.P. et al. What have we learned about heart failure with mid-range ejection fraction one year after its introduction? European Journal of Heart Failure. 2017: 1-5. DOI:10.1002/ejhf.1058.; Yancy C.W., Januzzi J.L. Jr., Allen L.A., et al. 2017 ACC expert consensus decision pathway for optimization of heart failure treatment: answers to 10 pivotal issues about heart failure with reduced ejection fraction: a report of the American College of Cardiology Task Force on Expert Consensus Decision Pathways. J Am Coll Cardiol. 2018;71:20-30. DOI:10.1016/j.jacc.2017.11.025; PMID: 29277252.; Koh A.S., Tay W.T., Teng T.H.K. et al. A comprehensive populationbased characterization of heart failure with mid-range ejection fraction. European Journal of Heart Failure. 2017:1-11. DOI:10.1002/ejhf.945.; Sartipy U., Dahlström U., Fu M. et al. Atrial Fibrillation in Heart Failure With Preserved, Mid-Range, and Reduced Ejection Fraction. JACC: Heart Failure. 2017:1-10. DOI:10.1016/j.jchf.2017.05.001.; Farmakis D., Simitsis P., Vasiliki B. et al. Acute Heart Failure with midrange ejection fraction: clinical profile, in-hospital management and short term outcome. Clin Res Cardiol. 2016: 1-10.; Tsuji K., Sakata Y., Nochioka K. et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction — a report from the CHART-2 Study. European journal of Heart Failure. 2017: 1-12. DOI:10.1002/ejhf.807.; Chioncel O., Lainscak M., Seferovic P.M. et al. Epidemiology and one-year outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. European Journal of Heart Failure. 2017; 12:1-12. DOI:10.1002/ejhf.813.; Tromp J., Voors A.A., Lam C.S.P. Heart failure with mid-range ejection fraction: causes and consequences. European Journal of Heart Failure. 2018: 1-3. DOI:10.1002/ejhf.1134.; Kapoor J.R., Kapoor R., Ju C. et al. Precipitating clinical factors, heart failure characterization, and outcomes in patients hospitalized with heart failure with reduced, borderline, and preserved ejection fraction. JACC Heart Fail. 2016;4:464–472. DOI:10.1016/j.jchf.2016.02.017.; Koh A.S., Tay W.T., Teng T.H. et al. A comprehensive population-based characterization of heart failure with mid-range ejection fraction. Eur J Heart Fail. 2017;19:1624–1634. DOI:10.1002/ejhf.945.; Vedin O., Lam C.S., Koh A.S. et al. Significance of ischemic heart disease in patients with heart failure and preserved, midrange, and reduced ejection fraction: a nationwide cohort study. Circ Heart Fail.2017; 10(6):1-9 DOI:10.1161/CIRCHEARTFAILURE.117.003875.; Chioncel O., Lainscak M., Seferovic P.M. et al. Epidemiology and oneyear outcomes in patients with chronic heart failure and preserved, mid-range and reduced ejection fraction: an analysis of the ESC Heart Failure Long-Term Registry. Eur J Heart Fail.2017; 19(12):1574-1585. DOI:10.1002/ejhf.813.; Rickenbacher P., Kaufmann B.A., Maeder M.T. et al. Heart failure with mid-range ejection fraction: a distinct clinical entity? Insights from the Trial of Intensified versus standard Medical therapy in Elderly patients with Congestive Heart Failure (TIME-CHF). Eur J Heart Fail 2017 12 15;19(12):1586-1596. DOI:10.1002/ejhf.798.; Yusuf S., Pfeffer M.A., Swedberg K. et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet Lond Engl. 2003;362:777–81. PMID: 13678871; Lufman I., Szummer K., Dahlstrцm U. et al. Associations with and prognostic impact of chronic kidney disease in heart failure with preserved, mid-range, and reduced ejection fraction. Eur J Heart Fail. 2017 Mar; 19(12):1606-1614. DOI:10.1002/ejhf.821.; Sartipy U., Dahlström U., Fu M. et al. Atrial fibrillation in heart failure with preserved, mid-range, and reduced ejection fraction. JACC Heart Fail.2017;5:565–574. DOI:10.1016/j.jchf.2017.05.001.; He K.L., Burkhoff D., Leng W.X., et al.Comparison of ventricular structure andfunction in Chinese patients with heartfailure and ejection fractions >55 % versus40 % to 55 % versus; Lang R.M., Badano L.P., Mor-Avi V. et al. Quantification by Echocardiography in Adults: An Update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging Guidelines and standards Journal of the American Society of Echocardiography Journal — Cardiovascular Imaging. 2015; 16, 233–271. DOI:10.1093/ehjci/jev014.; Moliner P., Lupón J., Barallat J. et al. A. Bio-profiling and bio-prognostication of chronic heart failure with mid-range ejection fraction. Int J Cardiol. 2017: 257:188-192. DOI:10.1016/j.ijcard.2018.01.119.; Tsuji K., Sakata Y., Nochioka K. et al. Characterization of heart failure patients with mid-range left ventricular ejection fraction—a report from the CHART-2 study. Eur. J. Heart Fail. 2017 Oct;19(10):1258-1269. DOI:10.1002/ejhf.807.; Bayes-Genis A., Nuñez-Villota J., Lupón J. Heart failure with midrange ejection fraction: a transition phenotype? Eur J Heart Fail. 2017 Dec;19(12):1635-1637. DOI:10.1002/ejhf.977.; Sanders-van Wijk S., Empel V., Davarzani N. et al. Circulating biomarkers of distinct pathophysiological pathways in heart failure with preserved vs. reduced left ventricular ejection fraction. Eur J Heart Fail. 2015 Oct; 17(10):1006-14. DOI:10.1002/ejhf.414.; Tromp J., Khan M.A.F., Mentz R.J. et al. Biomarker profiles of acute heart failure patientswith amid-range ejection fraction. JACC Heart Fail. 2017 Jul;5(7):507-517. DOI:10.1016/j.jchf.2017.04.007.; Kociol R.D., Pang P.S., Gheorghiade M. et al. Troponin elevation in heart failure prevalence, mechanisms, and clinical implications. J Am Coll Cardiol. 2010 Sep 28;56(14):1071-8. DOI:10.1016/j.jacc.2010.06.016.; Bayés-Genís A., Barallat J., Galán A. et al. Soluble neprilysin is predictive of cardiovascular death and heart failure hospitalization in heart failure patients. J Am Coll Cardiol. 2015 Feb 24;65(7):657-65. DOI:10.1016/j.jacc.2014.11.048.; Bayes-Genis A., Barallat J., Lupón J. Soluble neprilysin does not correlate with outcome in heart failure with preserved ejection fraction? Eur J Heart Fail. 2016 Jan;18(1):89-93. DOI:10.1002/ejhf.435.; Lupon J., Díez-Lуpez C., de Antonio M. et al. Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. Eur J Heart Fail. 2017 Dec;19(12):1615-1623. DOI:10.1002/ejhf.824.; Dunlay S.M., Roger V.L., Weston S.A. et al. Longitudinal changes in ejection fraction in heart failure patients with preserved and reduced ejection fraction. Circ Heart Fail. 2012 Nov;5(6):720-6. DOI:10.1161/CIRCHEARTFAILURE.111.966366.; Rastogi A., Novak E., Platts A. et al. Epidemiology, pathophysiology and clinical outcomes for heart failure patients with a mid-range ejection fraction. Eur J Heart Fail. 2017 Dec;19(12):1597-1605. DOI:10.1002/ejhf.879.; Unkovic P., Basuray A. Heart Failure with RecoveredEF and Heart Failurewith Mid-Range EF: CurrentRecommendationsand Controversies. Curr Treat Options Cardiovasc Med. 2018 Apr 3;20(4):35. DOI:10.1007/s11936-018-0628-9.; Clarke C.L., Grunwald G.K., Allen L.A. et al. Natural history of left ventricular ejection fraction in patients with heart failure. Circ Cardiovasc Qual Outcomes. 2013 Nov;6(6):680-6. DOI:10.1161/CIRCOUTCOMES.111.000045.; Nadruz W.Jr., West E., Santos M. et al. Heart Failure and Midrange Ejection Fraction: Implications of Recovered Ejection Fraction for Exercise Tolerance and Outcomes. Circ Heart Fail. 2016 Apr;9(4):e002826. DOI:10.1161/CIRCHEARTFAILURE.115.002826.; Basuray A., French B., Ky B. et al. Heart failure with recovered ejection fraction. Circulation. 2014 Jun 10;129(23):2380-7. DOI:10.1161/CIRCULATIONAHA.113.006855.; Kalogeropoulos A.P., Fonarow G.C., Georgiopoulou V. et al. Characteristics and outcomes of adult outpatients with heart failure and improved or recovered ejection fraction. JAMA Cardiol. 2016 Aug 1;1(5):510-8. DOI:10.1001/jamacardio.2016.1325.; Kelly J.P., Men R.J., Mebazaa A. et al. Patient selection in heart failure withpreserved ejection fraction clinical trials.J Am Coll Cardiol. 2015 Apr 28;65(16):1668-1682. DOI:10.1016/j.jacc.2015.03.043.; Cheng R.K., Cox M., Neely M.L. et al. Outcomes in patients with heart failurewith preserved, borderline, and reducedejection fraction in the Medicarepopulation. Am Heart J. 2014 Nov;168(5):721-30. DOI:10.1016/j.ahj.2014.07.008.; Pitt B., Pfeffer M.A., Assmann S.F.et al. TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014 Apr 10;370(15):1383-92. DOI:10.1056/NEJMoa1313731.; Cleland J.G.F., Bunting K.V., Flather M.D.et al. Beta-blockers for heart failure with reduced, mid-range, and preserved ejection fraction: an individual patient-level analysis of double-blind randomized trials. Eur Heart J. 2018 Jan 1;39(1):26-35. DOI:10.1093/eurheartj/ehx564.; Lofman I., Szummer K., Dahlstrom U. et al. Associations withand prognostic impact of chronic kidney disease in heartfailure with preserved, mid-range, and reduced ejectionfraction. Eur J Heart Fail.2017;19:1606–14. DOI:10.1002/ejhf.821;PMID: 28371075.; Nadar S.K., Tariq O. What is Heart Failure with Mid-range Ejection Fraction? A New Subgroup of Patients with Heart Failure. Cardiac Failure Review. 2018;4(1):6–8. DOI: https://doi.org/10.15420/cfr.2018:7:2Test.; Lund L.H., Claggett B., Liu J. et al. Heart failure with mid-range ejection fraction in CHARM: characteristics, outcomes and effect of candesartan across the entire ejection fraction spectrum. EurJHeart- Fail. 2018; DOI:10.1002/ejhf.1149; PMID: 29431256.; Хроническая сердечная недостаточность. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(11):4083. doi:10.15829/1560-4071-2020-4083.; Chronic heart failure. Clinical recommendations 2020. Russian journal of cardiology. 2020; 25 (11): 4083. doi:10.15829 / 1560-4071-2020-4083 [In Russian]; Леонова М.В. Европейский консенсус применения диуретиков при хронической сердечной недостаточности 2019 года. Медицинскийсовет. 2020;(4):12–21. doi:10.21518/2079-701X-2020-4-12-21.; Seferovic P.M., Ponikowski P., Anker S.D.et al. Clinical practice update on heart failure 2019: pharmacotherapy, procedures, devices and patient management. An expert consensus meeting report of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2019 Oct;21(10):1169-1186. doi:10.1002/ejhf.1531. Epub 2019 Aug 30. PMID: 31129923.; Pieske B., Tschöpe C., de Boer R.A. et al. How to diagnose heart failure with preserved ejection fraction: the HFA-PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC). Eur Heart J. 2019 Oct 21;40(40):3297-3317. doi:10.1093/eurheartj/ehz641. PMID: 31504452.; Nie D., Xiong B., Qian J.et al. The Effect of Sacubitril-Valsartan in Heart Failure Patients With Mid-Range and Preserved Ejection Fraction: A Meta-Analysis. Heart Lung Circ. 2020 Nov 13:S1443-9506(20)31475-X. doi:10.1016/j.hlc.2020.10.012. Epub ahead of print. PMID: 33199181.; Lam C.S.P., Doehner W., Comin-Colet J.; IRON CORE Group. Iron deficiency in chronic heart failure: case-based practical guidance. ESC Heart Fail. 2018;5(5):764-771. doi:10.1002/ehf2.12333.; https://www.medarhive.ru/jour/article/view/1171Test

الإتاحة: https://doi.org/10.20514/2226-6704-2021-11-2-111-121Test
https://doi.org/10.1016/j.ccl.2013.09.009Test
https://doi.org/10.1093/eurheartj/ehw128Test
https://doi.org/10.1002/ejhf.159Test
https://doi.org/10.1093/eurheartj/ehn309Test
https://doi.org/10.1093/eurheartj/ehs104Test
https://doi.org/10.1016/j.jchf.2016.03.025Test
https://doi.org/10.1002/ehf2.12283Test
https://doi.org/10.1016/j.jchf.2017.06.013Test
https://doi.org/10.1016/j.jacc.2017.11.025Test

View record in BASE

7

دورية أكاديمية

А САSЕ OF SPONTANEOUS CORONARY ARTERY DISSECTION (REVIEW AND CASE REPORT) ; СЛУЧАЙ СПОНТАННОЙ ДИССЕКЦИИ КОРОНАРНОЙ АРТЕРИИ (ОБЗОР ЛИТЕРАТУРЫ И ОПИСАНИЕ СЛУЧАЯ)

المؤلفون: N. T. Vatutin, G. G. Taradin, D. V. Bort, A. V. Dmitriev, I. V. Kanisheva, I. A. Sidorenko, Н. Т. Ватутин, Г. Г. Тарадин, Д. В. Борт, А. В. Дмитриев, И. В. Канишева, И. А. Сидоренко

المصدر: The Russian Archives of Internal Medicine; Том 9, № 1 (2019); 23-30 ; Архивъ внутренней медицины; Том 9, № 1 (2019); 23-30 ; 2411-6564 ; 2226-6704 ; 10.20514/2226-6704-2019-9-1

مصطلحات موضوعية: постпартальный период, myocardial infarction, cardiogenic shock, diagnosis, coronary angiography, treatment, pregnancy, postpartum period, инфаркт миокарда, кардиогенный шок, диагностика, коронарография, лечение, беременность

وصف الملف: application/pdf

العلاقة: https://www.medarhive.ru/jour/article/view/880/757Test; https://www.medarhive.ru/jour/article/view/880/765Test; Протасова Е.А., Фурман Н.В., Титков И.В. и др. Спонтанная диссекция коронарной артерии как причина развития острого инфаркта миокарда. Кардиоваскулярная терапия и профилактика. 2014; 13(5):70-73. doi:10.15829/1728-8800-2014-5-70-73.; Pretty H.C. Dissecting aneurysm of coronary artery in a woman aged 42: rupture. Br Med J. 1931;1:667. doi:10.1136/bmj.1.3667.667.; Hayes S.N., Kim E.S.H., Saw J., et al. Spontaneous coronary artery dissection: current state of the science: a scientific statement from the American Heart Association. Circulation. 2018;137(19):e523-e557. doi:10.1161/CIR.0000000000000564.; Rogowski S., Maeder M.T., Weilenmann D., et al. Spontaneous coronary artery dissection: angiographic follow-up and longterm clinical outcome in a predominantly medically treated population. Catheter Cardiovasc Interv. 2017;89:59–68. doi:10.1002/ccd.26383.; Elkayam U., Jalnapurkar S., Barakkat M.N., et al. Pregnancy-associated acute myocardial infarction: a review of contemporary experience in 150 cases between 2006 and 2011. Circulation. 2014;129:1695–1702. doi:10.1161/CIRCULATIONAHA.113.002054.; Rashid H.N., Wong D.T., Wijesekera H., et al. Incidence and characterisation of spontaneouscoronary artery dissection as a cause of acute coronary syndrome:a single-centre Australian experience. Int J Cardiol. 2016;202:336–338. doi:10.1016/j.ijcard.2015.09.072.; Kwon T.G., Gulati R., Matsuzawa Y., et al. Proliferation of coronary adventitial vasa vasorum in patients with spontaneous coronary artery dissection. JACC Cardiovasc Imaging. 2016;9:891–892. doi:10.1016/j.jcmg.2015.11.030.; Alfonso F., Paulo M., Gonzalo N., et al. Diagnosis of spontaneous coronary artery dissection by optical coherence tomography. J Am Coll Cardiol. 2012;59:1073–1079. doi:10.1016/j.jacc.2011.08.082.; Desai S., Sheppard M.N. Sudden cardiac death: look closely at the coronaries for spontaneous dissection which can be missed: a study of 9 cases. Am J Forensic Med Pathol. 2012;33:26–29. doi:10.1097/PAF.0b013e3181e29598.; Saw J., Ricci D., Starovoytov A., et al. Spontaneous coronary artery dissection: prevalence of predisposing conditions including fibromuscular dysplasia in a tertiary center cohort. JACC Cardiovasc Interv. 2013;6:44–52. doi:10.1016/j.jcin.2012.08.017.; Olin J.W., Gornik H.L., Bacharach J.M., et al. Fibromuscular dysplasia: state of the science and critical unanswered questions: a scientific statement from the American Heart Association. Circulation. 2014;129:1048–1078. doi:10.1161/01.cir.0000442577.96802.8c.; Saw J. Coronary angiogram classification of spontaneous coronary artery dissection. Catheter Cardiovasc Interv. 2014;84:1115–1122. doi:10.1002/ccd.25293.; Codsi E., Tweet M.S., Rose C.H., et al. Spontaneous coronary artery dissection in pregnancy: what every obstetrician should know. Obstet Gynecol. 2016;128:731–738. doi:10.1097/AOG.0000000000001630.; Saw J., Mancini G.B.J., Humphries KH. Contemporary review on spontaneous coronary artery dissection. J Am Coll Cardiol. 2016;68:297–312. doi:10.1016/j.jacc.2016.05.034.; Cade J.R., Szarf G., de Siqueira M.E., et al. Pregnancy-associated spontaneous coronary artery dissection: insights from a case series of 13 patients. Eur Heart J Cardiovasc Imaging. 2017; 18:54–61. doi:10.1093/ehjci/jew021.; Henkin S., Negrotto S.M., Tweet M.S., et al. Spontaneous coronary artery dissection and its association with heritable connective tissue disorders. Heart. 2016;102:876–883. doi:10.1136/heartjnl-2015-308645.; Tweet M.S., Hayes S.N., Pitta S.R., et al. Clinical features, management, and prognosis of spontaneous coronary artery dissection. Circulation. 2012;126:579–588. doi:10.1161/CIRCULATIONAHA.112.105718.; Nakamoto K., Matsuda M., Kanno K., et al. A case of a young, healthy woman with spontaneous coronary artery dissection associated with oral contraceptive use: long-term residual dissection of the coronary artery. J Cardiol Cases. 2013; 8:179–182. DOI:10.1161/CIR.0000000000000564.; Saw J., Aymong E., Sedlak T., et al. Spontaneous coronary artery dissection: association with predisposing arteriopathies and precipitating stressors and cardiovascular outcomes. Circ Cardiovasc Interv. 2014;7:645–655. doi:10.1016/j.jcin.2012.08.017.; Tweet M.S., Eleid M.F., Best P.J., et al. Spontaneous coronary artery dissection: revascularization versus conservative therapy. Circ Cardiovasc Interv. 2014;7:777–786. doi:10.1161/CIRCINTERVENTIONS.114.001659.; Alfonso F., Paulo M., Dutary J. Endovascular imaging of angiographically invisible spontaneous coronary artery dissection. JACC Cardiovasc Interv. 2012 Apr;5(4):452-3. doi:10.1016/j.jcin.2012.01.016.; Hollander J.E., Than M, Mueller C. State-of-the-art evaluation of emergency department patients presenting with potential acute coronary syndromes. Circulation. 2016;134:547–564. doi:10.1161/CIRCULATIONAHA.116.021886.; Alkhouli M., Cole M., Ling F.S. Coronary artery fenestration prior to stenting in spontaneous coronary artery dissection. Catheter Cardiovasc Interv. 2016;88:E23–E27. doi:10.1002/ccd.26161.; Tweet M.S., Gulati R., Hayes S.N. What clinicians should know αbout spontaneous coronary artery dissection. Mayo Clin Proc. 2015;90:1125–1130. doi:10.1016/j.mayocp.2015.05.010.; Jneid H., Anderson J.L., Wright R.S., et al. 2012 ACCF/AHA focused update of the guideline for the management of patients with unstable angina/non-ST-elevation myocardial infarction (updating the 2007 guideline and replacing the 2011 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation. 2012;126:875–910. doi:10.1161/CIR.0b013e318256f1e0.; Ватутин Н.Т., Тарадин Г.Г., Попелнухина Л.Г. и др. Лечение перипартальной кардиомиопатии. Архивъ внутренней медицины. 2017; 7(5): 340-349. DOI:10.20514/2226-6704-2017-7-5-340-349.; Ватутин Н.Т., Тарадин Г.Г., Тараторина А.А. и др. Ишемическая болезнь сердца и беременность. Медико-социальные проблемы семьи. 2013; 18(4): 97-106.; Elkayam U., Goland S., Pieper P.G., Silverside C.K. Highrisk cardiac disease in pregnancy, part I. J Am Coll Cardiol. 2016;68:396–410. doi:10.1016/j.jacc.2016.05.048.; Regitz-Zagrosek V., Blomstrom Lundqvist C., Borghi C., et al. ESC guidelines on the management of cardiovascular diseases during pregnancy: the Task Force on the Management of Cardiovascular Diseases during Pregnancy of the European Society of Cardiology (ESC). Eur Heart J. 2011;32:3147–3197. doi:10.1093/eurheartj/ehr218.; Peacock W.F., Hilleman D.E., Levy P.D., et al. A systematic review of nicardipine vs labetalol for the management of hypertensive crises. Am J Emerg Med. 2012;30:981–993. doi:10.1016/j.ajem.2011.06.040.; https://www.medarhive.ru/jour/article/view/880Test

View record in BASE

8

دورية أكاديمية

CURRENT VIEW ON ANTICOAGULANT AND THROMBOLYTIC TREATMENT OF ACUTE PULMONARY EMBOLISM ; СОВРЕМЕННЫЕ ВЗГЛЯДЫ НА АНТИКОАГУЛЯНТНУЮ И ТРОМБОЛИТИЧЕСКУЮ ТЕРАПИЮ ОСТРОЙ ЛЕГОЧНОЙ ЭМБОЛИИ

المؤلفون: G. A. Ignatenko, G. G. Taradin, N. T. Vatutin, I. V. Kanisheva, Г. А. Игнатенко, Г. Г. Тарадин, Н. Т. Ватутин, И. В. Канишева

المصدر: The Russian Archives of Internal Medicine; Том 9, № 5 (2019); 348-366 ; Архивъ внутренней медицины; Том 9, № 5 (2019); 348-366 ; 2411-6564 ; 2226-6704 ; 10.20514/2226-6704-2019-0-5

مصطلحات موضوعية: геморрагические осложнения, venous thromboembolism, thromboembolism of pulmonary artery, treatment, risk stratification, anticoagulant therapy, direct oral anticoagulants, systemic thrombolysis, fibrinolysis, bleeding complications, венозная тромбоэмболия, тромбоэмболия легочной артерии, лечение, стратификация риска, антикоагулянтная терапия, прямые оральные антикоагулянты, системный тромболизис, фибринолиз

وصف الملف: application/pdf

العلاقة: https://www.medarhive.ru/jour/article/view/963/835Test; https://www.medarhive.ru/jour/article/view/963/842Test; Konstantinides S.V., Torbicki A., Agnelli G., et al. 2014 ESC Guidelines on the diagnosis and management of acute pulmonary embolism: the task force for the diagnosis and management of acute pulmonary embolism of the European Society of Cardiology (ESC) endorsed by the european respiratory society (ERS). European Heart Journal. 2014; 35(43): 3033–69, 3069a-3069k. DOI:10.1093/eurheartj/ehu283.; Tritschler T, Kraaijpoel N, Le Gal G, Wells PS. Venous thromboembolism: advances in diagnosis and treatment. JAMA. 2018 Oct 16;320(15):1583-1594. doi:10.1001/jama.2018.14346.; Tagalakis V, Patenaude V, Kahn SR, Suissa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE Study Cohort. Am J Med. 2013;126(9): 832.e13-832. doi:10.1016/j.amjmed.2013.02.024; Konstantinides S.V., Barco S., Lankeit M., Meyer G. Management of pulmonary embolism: an update. J Am Coll Cardiol. 2016 Mar 1;67(8):976-90. doi:10.1016/j.jacc.2015.11.061.; Carrier M, Righini M, Wells PS, et al. Subsegmental pulmonary embolism diagnosed by computed tomography: incidence and clinical implications: a systematic review and meta-analysis of the management outcome studies. J Thromb Haemost. 2010;8(8):1716-1722. doi:10.1111/j.1538-7836.2010.03938.x; Ватутин Н.Т., Тарадин Г.Г., Канишева И.В. и др. Роль интервенционных методов в лечении острой легочной эмболии. Архивъ внутренней медицины. 2018; 8(5):346-360. doi:10.20514/22266704-2018-0-5-346-360.; Torbicki A, Perrier A, Konstantinides S, et al.; ESC Committee for Practice Guidelines (CPG). Guidelines on the diagnosis and management of acute pulmonary embolism: the Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology (ESC). Eur Heart J. 2008 Sep;29(18):2276-315. doi:10.1093/eurheartj/ehn310.; Jaff M.R., McMurtry M.S., Archer S.L., et al. Management of massive and submassive pulmonary embolism, iliofemoral deep vein thrombosis, and chronic thromboembolic pulmonary hypertension: a Scientific Statement from the American Heart Association. Circulation 2011;123(16):1788-830. doi:10.1161/CIR.0b013e318214914f.; Sekhri V, Mehta N, Rawat N, et al. Management of massive and nonmassive pulmonary embolism. Arch Med Sci. 2012 Dec 20; 8(6):957-69. doi:10.5114/aoms.2012.32402.; Bĕlohlavek J, Dytrych V, Linhart A. Pulmonary embolism, part I: Epidemiology, risk factors and risk stratification, pathophysiology, clinical presentation, diagnosis and nonthrombotic pulmonary embolism. Exp Clin Cardiol. 2013 Spring;18(2):129-38.; Corrigan D, Prucnal C, Kabrhel C. Pulmonary embolism: the diagnosis, risk-stratification, treatment and disposition of emergency department patients. Clin Exp Emerg Med. 2016 Sep; 3(3): 117–125. doi:10.15441/ceem.16.146; Miller G.A., Sutton G.C., Kerr I.H., et al. Comparison of streptokinase and heparin in treatment of isolated acute massive pulmonary embolism. Br Med J. 1971;2:681– 684.; Aujesky D., Obrosky D.S., Stone R.A., et al. Derivation and validation of a prognostic model for pulmonary embolism. Am. J. Respir. Crit. Care Med. 2005;172: 1041–1046.; Jimenez D, Aujesky D, Moores L, et al.; RIETE Investigators. Simplification of the pulmonary embolism severity index for prognostication in patients with acute symptomatic pulmonary embolism. Arch Intern Med 2010 Aug 9;170(15):1383-9. doi:10.1001/archinternmed.2010.199; Huisman M.V., Barco S., Cannegieter S.C., et al. Pulmonary embolism. Nat. Rev. Dis. Primers. 2018 May 17;4:18028. doi:10.1038/nrdp.2018.28.; Kabrhel C., Jaff M.R., Channick R.N., et al. A multidisciplinary pulmonary embolism response team. CHEST Journal. 2013; 144(5):1738-1739.; Root C.W., Dudzinski D.M., Zakhary B., et al. Multidisciplinary approach to the management of pulmonary embolism patients: the pulmonary embolism response team (PERT). J Multidiscip Healthc. 2018 Apr 5;11:187-195. doi:10.2147/JMDH.S151196.; Petriş AO, Konstantinides S, Tint D, et al. Therapeutic advances in emergency cardiology: acute pulmonary embolism. Am J Ther. 2019 Mar/Apr;26(2):e248-e256. doi:10.1097/MJT.0000000000000917.; Barritt DW, Jordan SC. Anticoagulant drugs in the treatment of pulmonary embolism. Lancet 1960;275(7138):1309–12.; Jolly M., Phillips J. Pulmonary embolism: current role of catheter treatment options and operative thrombectomy. Surg. Clin. North. Am. 2018 Apr;98(2):279-292. doi:10.1016/j.suc.2017.11.009.; Chopard R, Andarelli JN, Humbert S, et al. Prescription patterns of direct oral anticoagulants in pulmonary embolism: A prospective multicenter French registry. Thromb Res. 2019 Feb;174:27-33. doi:10.1016/j.thromres.2018.12.013.; Stein PD, Dalen JE, Matta F, et al. Optimal therapy for unstable pulmonary embolism. Am J Med. 2019 Feb;132(2):168-171. doi:10.1016/j.amjmed.2018.09.018.; Borohovitz A, Weinberg MD, Weinberg I. Pulmonary embolism: Care standards in 2018. Prog Cardiovasc Dis. 2018 Mar — Apr;60(6):613621. doi:10.1016/j.pcad.2017.12.005.; Hepburn-Brown M, Darvall J, Hammerschlag G. Acute pulmonary embolism: a concise review of diagnosis and management. Intern Med J. 2019 Jan;49(1):15-27. doi:10.1111/imj.14145; Kearon C, AgenoW, Cannegieter SC, et al.; Subcommittees on Control of Anticoagulation, and Predictive and Diagnostic Variables in Thrombotic Disease. Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH. J Thromb Haemost. 2016;14(7):1480-1483. doi:10.1111/jth.13336; Carrier M., Le G.G., Wells P.S., et al. Systematic review: case-fatality rates of recurrent venous thromboembolism and major bleeding events among patients treated for venous thromboembolism. Ann. Intern. Med. 2010 May 4;152(9):578-89. doi:10.7326/0003-4819-152-9201005040-00008.; Witt DM, Nieuwlaat R, Clark NP, et al. American Society of Hematology 2018 guidelines for management of venous thromboembolism: optimal management of anticoagulation therapy. Blood Adv. 2018 Nov 27;2(22):3257-3291. doi:10.1182/bloodadvances.2018024893.; Kearon C., Akl E.A., Ornelas J., et al. Antithrombotic therapy for VTE disease: CHEST guideline and expert panel report. Chest. 2016;149(2):315-352. doi:10.1016/j.chest.2015.11.026.; Heidbuchel H., Verhamme P., Alings M., et al. EHRA practical guide on the use of new oral anticoagulants in patients with nonvalvular atrial fibrillation: executive summary. Eur Heart J. 2013 Jul; 34(27): 20942106. doi:10.1093/eurheartj/eht134.; Beyer-Westendorf J., Verhamme P., Bauersachs R. Betrixaban for prevention of venous thromboembolism in acute medically ill patients. Eur Heart J Suppl. 2018 May;20(Suppl E):E16-E22. doi:10.1093/eurheartj/suy017; van Es N., Coppens M., Schulman S., et al. Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood 2014; Sep 18; 124(12):1968-75. doi:10.1182/blood-2014-04-571232.; van der Hulle T., Kooiman J., den Exter P.L., et al. Effectiveness and safety of novel oral anticoagulants as compared with vitamin K antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and meta-analysis. J. Thromb. Haemost. 2014;12(3):320-8. doi:10.1111/jth.12485.; Arcadi FA, Portaro S, Giorgianni R, et al. New versus old oral anticoagulants: how can we set the scale needle? Considerations on a case report. Medicina (Kaunas). 2019 Mar 17;55(3). pii: E71. doi:10.3390/medicina55030071; Dawwas GK, Brown J, Dietrich E, et al. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Lancet Haematol. 2019 Jan;6(1):e20-e28. doi:10.1016/S23523026(18)30191-1.; Schulman S., Kearon C., Kakkar A.K., et al.; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361(24):2342-52. doi:10.1056/NEJMoa0906598.; Schulman S., Kakkar A.K., Goldhaber S.Z., et al.; RE-COVER II Trial Investigators. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129(7):764-72. doi:10.1161/CIRCULATIONAHA.113.004450; Bauersachs R., Berkowitz S.D., Brenner B., et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363(26):2499-510. doi:10.1056/NEJMoa1007903.; Buller H.R., Prins M.H., Lensin A.W., et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366(14):1287-97. doi:10.1056/NEJMoa1113572; Agnelli G., Buller H.R., Cohen A., et al; AMPLIFY Investigators. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369(9):799-808. doi:10.1056/NEJMoa1302507.; Buller H.R., Decousus H., Grosso M.A., et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369(15):1406-15. doi:10.1056/NEJMoa1306638.; Martin K., Beyer-Westendorf J., Davidson B.L., et al. Use of the direct oral anticoagulants in obese patients: guidance from the SSC of the ISTH. J. Thromb. Haemost. 2016 Jun;14(6):1308-13. doi:10.1111/jth.13323.; Piran S, Schulman S. Treatment of bleeding complications in patients on anticoagulant therapy. Blood. 2019;133(5):425-435. doi:10.1182/blood-2018-06-820746; Shakur H, Roberts I, Bautista R, et al.; CRASH-2 trial collaborators. Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): a randomised, placebo-controlled trial. Lancet. 2010; 376(9734):23-32. doi:10.1016/S0140-6736(10)60835-5.; Douxfils J, Gosselin RC. Laboratory assessment of direct oral anticoagulants. Semin Thromb Hemost. 2017 Apr;43(3):277-290. doi:10.1055/s-0036-1597296; Mosarla RC, Vaduganathan M, Qamar A, et al. Anticoagulation strategies in patients with cancer: JACC Review Topic of the Week. J Am Coll Cardiol. 2019 Mar 26;73(11):1336-1349. doi:10.1016/j.jacc.2019.01.017; Lee AY, Levine MN, Baker RI, et al. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003 Jul 10; 349(2):146-53.; Lee AYY, Kamphuisen PW, Meyer G, et al.; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized clinical trial. JAMA. 2015 Aug 18;314(7):677-686. doi:10.1001/jama.2015.9243.; Raskob GE, van Es N, Verhamme P, et al.; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378:615–24. doi:10.1056/NEJMoa1711948; Young A, Marshall A, Thirlwall J, et al. Anticoagulation therapy in selected cancer patients at risk of recurrence of venous thromboembolism: results of the Select-D Pilot Trial. Blood 2017; 130:625.; Li A, Garcia DA, Lyman GH, et al. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for treatment of cancer associated thrombosis (CAT): A systematic review and meta-analysis. Thromb Res 2018: doi:10.1016/j.thromres.2018.02.144.; Peacock WF, Singer AJ. Reducing the hospital burden associated with the treatment of pulmonary embolism. J Thromb Haemost. 2019 Mar 9. doi:10.1111/jth.14423; Khorana AA, Noble S, Lee AYY, et al. Role of direct oral anticoagulants in the treatment of cancer-associated venous thromboembolism: guidance from the SSC of the ISTH. J Thromb Haemost 2018 Sep;16(9):1891-1894. doi:10.1111/jth.14219.; Bartel B. Systemic thrombolysis for acute pulmonary embolism. Hosp. Pract. 2015;43(1):22-7. doi:10.1080/21548331.2015.1001302.; Konstantinides S.V., Barco S. Systemic thrombolytic therapy for acute pulmonary embolism: who is a candidate? Semin. Respir. Crit. Care Med. 2017 Feb;38(1):56-65. doi:10.1055/s-0036-1597560.; Marti C., John G., Konstantinides S., et al. Systemic thrombolytic therapy for acute pulmonary embolism: a systematic review and meta-analysis. Eur Heart J 2015; 36(10):605-14. doi:10.1093/eurheartj/ehu218.; Stein P.D., Matta F. Thrombolytic therapy in unstable patients with acute pulmonary embolism: saves lives but underused. Am J Med. 2012; 125(5):465-70. doi:10.1016/j.amjmed.2011.10.015.; Murphy E, Lababidi A, Reddy R, et al. The role of thrombolytic therapy for patients with a submassive pulmonary embolism. Cureus. 2018;10(6):e2814. doi:10.7759/cureus.2814; Virk HUH, Chatterjee S, Sardar P, et al. Systemic thrombolysis for pulmonary embolism: evidence, patient selection, and protocols for management. Interv Cardiol Clin. 2018 Jan;7(1):71-80. doi:10.1016/j.iccl.2017.08.001.; Никитина О.В., Михайлов И.П., Кудряшова Н.Е. и др. Тромболитическая и антикоагулянтная терапия при тромбоэмболии легочной артерии: влияние на легочную перфузию (часть 2). Журнал им. Н.В. Склифосовского Неотложная медицинская помощь. 2018; 7(2): 134–143. DOI:10.23934/2223-9022-2018-7-2-134-143.; Becattini C, Agnelli G, Salvi A, et al. Bolus tenecteplase for right ventricle dysfunction in hemodynamically stable patients with pulmonary embolism. Thromb Res. 2010;125(3):e82–e86. doi:10.1016/j.thromres.2009.09.017; Jerjes-Sanchez C, Ramirez-Rivera A, de Lourdes Garcia M, et al. Streptokinase and heparin versus heparin alone in massive pulmonary embolism: a randomized controlled trial. J Thromb Thrombolysis. 1995;2(3):227-229.; Kline J.A., Steuerwald M.T., Marchick M.R., et al. Prospective evaluation of right ventricular function and functional status 6 months after acute submassive pulmonary embolism: frequency of persistent or subsequent elevation in estimated pulmonary artery pressure. Chest 2009;136:1202-10.; Chatterjee S, Chakraborty A, Weinberg I, et al. Thrombolysis for pulmonary embolism and risk of all-cause mortality, major bleeding, and intracranial hemorrhage: a meta-analysis. JAMA. 2014 Jun 18; 311(23):2414-21. doi:10.1001/jama.2014.5990; Bougouin W., Marijon E., Planquette B., et al.; on behalf from the Sudden Death Expertise Center. Pulmonary embolism related sudden cardiac arrest admitted alive at hospital: Management and outcomes. Resuscitation. 2017;115:135-140. doi:10.1016/j.resuscitation.2017.04.019.; Zuin M, Rigatelli G, Carraro M, et al. Systemic thrombolysis in haemodynamically unstable pulmonary embolism: The earlier the better? Thromb Res. 2019 Jan;173:117-123. doi:10.1016/j.thromres.2018.11.029.; Fernandes CJCDS, Jardim CVP, Alves JL Jr, et al. Reperfusion in acute pulmonary thromboembolism. J Bras Pneumol. 2018 Jun 7:0. doi:10.1590/S1806-37562017000000204.; Becattini C., Agnelli G., Lankeit M., et al. Acute pulmonary embolism: mortality prediction by the 2014 European Society of Cardiology risk stratification model. Eur. Respir. J. 2016;48(3):780-6. doi:10.1183/13993003.00024-2016.; Kline JA, Nordenholz KE, Courtney DM, et al. Treatment of submassive pulmonary embolism with tenecteplase or placebo: cardiopulmonary outcomes at 3 months: multicenter double-blind, placebo-controlled randomized trial. J Thromb Haemost. 2014 Apr;12(4):459-68. doi:10.1111/jth.12521.; Konstantinides S., Geibel A., Heusel G., et al.; Management Strategies and Prognosis of Pulmonary Embolism-3 Trial Investigators. Heparin plus alteplase compared with heparin alone in patients with submassive pulmonary embolism. N Engl J Med. 2002 Oct 10; 347(15):1143-50.; Sharifi M., Bay C., Skrocki L., et al.; “MOPETT” Investigators. Moderate pulmonary embolism treated with thrombolysis (from the “MOPETT” Trial). Am J Cardiol. 2013;111(2):273-7. doi:10.1016/j.amjcard.2012.09.027.; Riva N., Puljak L., Moja L., et al. Multiple overlapping systematic reviews facilitate the origin of disputes: the case of thrombolytic therapy for pulmonary embolism. J Clin Epidemiol. 2018;97:1-13. doi:10.1016/j.jclinepi.2017.11.012.; Teleb M, Porres-Aguilar M, Anaya-Ayala JE, et al. Potential role of systemic thrombolysis in acute submassive intermediate risk pulmonary embolism: review and future perspectives. Ther Adv Cardiovasc Dis. 2016;10(2):103–110. doi:10.1177/1753944716630694; Meyer G., Vicaut E., Danays T., et al.; PEITHO Investigators. Fibrinolysis for patients with intermediate-risk pulmonary embolism. N Engl J Med 2014; 370(15):1402-11. doi:10.1056/NEJMoa1302097.; Miranda CH. Use of thrombolytic agents in the treatment of acute pulmonary thromboembolism: things are not as simple as you might think. J Bras Pneumol. 2019 Feb 11;45(1):e20180297. doi:10.1590/1806-3713/e20180297.; Klok F.A., Dzikowska-Diduch O., Kostrubiec M., et al. Derivation of a clinical prediction score for chronic thromboembolic pulmonary hypertension after acute pulmonary embolism. J. Thromb. Haemost. 2016;14(1):121-8. doi:10.1111/jth.13175; Goldhaber S.Z. PEITHO Long-Term Outcomes Study: Data Disrupt Dogma. J Am Coll Cardiol. 2017 Mar 28;69(12):1545-1548. doi:10.1016/j.jacc.2017.01.027.; Konstantinides S.V., Vicaut E., Danays T., et al. Impact of thrombolytic therapy on the long-term outcome of intermediate-risk pulmonary embolism. J Am Coll Cardiol. 2017;69(12):1536-1544. doi:10.1016/j.jacc.2016.12.039.; Jimenez D, de Miguel-Diez J, Guijarro R, et al; RIETE Investigators. Trends in the management and outcomes of acute pulmonary embolism: analysis from the RIETE Registry. J Am Coll Cardiol. 2016;67(2):162–170 doi:10.1016/j.jacc.2015.10.060.; Wang C, Zhai Z, Yang Y, et al.; China Venous Thromboembolism (VTE) Study Group. Efficacy and safety of low dose recombinant tissue-type plasminogen activator for the treatment of acute pulmonary thromboembolism: a randomized, multicenter, controlled trial. Chest 2010; Feb;137(2):254-62. doi:10.1378/chest.09-0765.; Kiser TH, Burnham EL, Clark B, et al. Half-dose versus full-dose alteplase for treatment of pulmonary embolism. Crit Care Med. 2018 Oct;46(10):1617-1625. doi:10.1097/CCM.0000000000003288.; Jin Q, Luo Q, Zhao Z, et al. Half-dose versus full-dose alteplase therapy in pulmonary embolism: does half dose really lose? Crit Care Med. 2018 Dec;46(12):e1223-e1224. doi:10.1097/CCM.0000000000003384; Rothschild DP, Goldstein JA, Bowers TR. Low-dose systemic thrombolytic therapy for treatment of submassive pulmonary embolism: Clinical efficacy but attendant hemorrhagic risks. Catheter Cardiovasc Interv. 2019 Feb 15;93(3):506-510. doi:10.1002/ccd.28042.; Halaby R, Giri J. Keep it simple? Half-dose systemic thrombolysis or catheter-directed thrombolysis for pulmonary embolism. Vasc Med. 2019 Mar 5:1358863X18824653. doi:10.1177/1358863X18824653.; https://www.medarhive.ru/jour/article/view/963Test

View record in BASE

9

دورية أكاديمية

THE USE OF MINERALOCORTICOID RECEPTOR ANTAGONISTS IN THE PRE VENTION OF ATRIAL FIBRILLATION ; ПЕРСПЕКТИВЫ ПРИМЕНЕНИЯ АНТАГОНИСТОВ МИНЕРАЛОКОРТИКОИДНЫХ РЕЦЕПТОРОВ В ПРОФИЛАКТИКЕ ФИБРИЛЛЯЦИИ ПРЕДСЕРДИЙ (ОБЗОР ЛИТЕРАТУРЫ И СОБСТВЕННЫЕ ДАННЫЕ)

المؤلفون: N. T. Vatutin, A. N. Shevelok, G. G. Taradin, I. N. Kravchenko, Н. Т. Ватутин, А. Н. Шевелёк, Г. Г. Тарадин, И. Н. Кравченко

المصدر: The Russian Archives of Internal Medicine; Том 9, № 4 (2019); 260-268 ; Архивъ внутренней медицины; Том 9, № 4 (2019); 260-268 ; 2411-6564 ; 2226-6704 ; 10.20514/2226-6704-2019-9-4

مصطلحات موضوعية: спиронолактон, renin-angiotensin-aldosterone system, atrial fibrillation, relapses, eplerenone, spironolactone, ренин-ангиотензин-альдостероновая система, фибрилляция предсердий, рецидивы, эплеренон

وصف الملف: application/pdf

العلاقة: https://www.medarhive.ru/jour/article/view/946/814Test; https://www.medarhive.ru/jour/article/view/946/824Test; Kirchhof P., Benussi S., Kotecha D. et al. 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur. Heart J. 2016; 37(38): 2893-2962.; Ревишвили А.Ш., Антонченко И.В., Ардашев А.В. и др. Аритмология: клинич. рекомендации по проведению электрофизиологических исследований, катетерной аблации и применению имплантируемых антиаритмических устройств. М.: ГЭОТАР-Медиа 2010: 304 Revishvili A.Sh., Antonchenko I.V., Ardashev A.V. et al Arrhythmology: clinical guidelines for electrophysiological studies, catheter ablation and implantable cardioverter. M.: GEOTAR Media, 2010: 304. [In Russian].; Апарина О.П., Чихирева Л.Н., Миронова Н.А. и др. Роль изменений структуры и функции предсердий в развитии и прогрессировании фибрилляции предсердий. Терапевтический архив. 2014; 1: 71-77. Aparina O.P., Chigireva L.N., Mironova N.A. et al. The Role of changes in the structure and function of the Atria in the development and progression of atrial fibrillation. Therapeutic archive. 2014; 1: 71-77. [In Russian]; Khatib R., Joseph P., Briel M. et al. Blockade of the renin-angiotensinaldosterone system for primary prevention of nonvalvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials Int. J. Cardiol. 2013; 165(1): 17-24. DOI:10.1016/j. ijcard.2012.02.009; Fuller P.J., Young M.J. Endocrine Affairs of the Heart. Endocrinology 2016; 157(7): 2578-2582. DOI:10.1210/en.2016-1375; Mayyas F., Karem Alzoubi H., Van Wagoner D.R. Impact of aldosterone antagonists on the substrate for atrial fibrillation: Aldosterone promotes oxidative stress and atrial structural:electrical remodeling. Int. J. Cardiol. 2013; 168(6):5135–5142. DOI:10.1016/j. ijcard.2013.08.022; Ватутин Н.Т., Шевелек А.Н., Кравченко И.Н. Роль гиперальдостеронемии в возникновении рецидивов фибрилляции предсердий. Сердце: журнал для практикующих врачей. 2016; 24(3): 161-165. Vatutin N.T., Shevelok A.N., Kravchenko I.N. et al. The role of hyperaldosteronism in appearance of recurrence of atrial fibrillation. Heart: the journal for practitioners. 2016; 24(3): 161-165. [In Russian]; Milliez P., Girerd X., Plouin P.F. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 2005; 45: 1243-1248.; Harvey A.M. Hyperaldosteronism: diagnosis, lateralization, and treatment. Surg. Clin. North Am. 2014; 94(3): 643-656. DOI:10.1016/j.suc.2014.02.007; Ватутин Н.Т., Шевелёк А.Н., Дегтярева А.Э. и др. Роль гиперальдостеронизма и перспективы применения антагонистов альдостерона при резистентной артериальной гипертензии. Журнал национальной академии медицинских наук. 2014; 20(1): 43-52 Vatutin N.T., Shevelok A.N., Degtyarev A.E. et al. The Role of hyperaldosteronism and prospects for the use of aldosterone antagonists in resistant hypertension. The national journal of the Academy of medical Sciences. 2014; 20(1): 43-52. [In Russian]; Riet L.Te, Esch van J.H., Roks A.J. et al. Hypertension: reninangiotensin-aldosterone system alterations. Circ. Res. 2015; 116(6): 960-975. DOI:10.1161/CIRCRESAHA.116.303587; Lantis A.C., Ames M.K., Atkins C.E. et al. Aldosterone breakthrough with benazepril in furosemide-activated renin-angiotensinaldosteronesystem in normal dogs. J. Vet. Pharmacol. Ther. 2015; 38(1): 65-73. DOI:10.1111/jvp.12154; Takahashi H., Sato T., Ikeuchi T. et al. High levels of plasma cortisol and impaired hypoosmoregulation in a mutant medaka deficient in P450c17I. Mol. Cell. Endocrinol. 2016; 15(430): 25-32.; Канорский С.Г. Антиаритмическая терапия у пациентов с пароксизмальной и персистирующей формами фибрилляции предсердий: определение достижимой цели и оценка имеющихся средств. Кардиология. 2014; 54(2): 70-74 Kanorsky S.G. Antiarrhythmic therapy in patients with paroxysmal and persistent forms of atrial fibrillation: defining achievable goals and assessment of available funds. Cardiology. 2014; 54(2): 70-74. [In Russian]; Ватутин Н.Т., Калинкина Н.В., Шевелёк А.Н. Профилактика пароксизмов фибрилляции предсердий противоаритмическими препаратами. Актуальные вопросы медицинской науки и практики. 2008; 74: 21-35. Vatutin N.T., Kalinkina N.V., Shevelok A.N. Prevention of paroxysms of atrial fibrillation by antiarrhythmic drugs. Current issues of medical science and practice. 2008; 74: 21-35. [In Russian]; Канорский С.Г. Лечение больных с фибрилляцией предсердий: поиск оптимальных решений. Кардиология. 2016; 56(8): 46-53. Kanorsky S.G. Treatment of patients with atrial fibrillation: the search for optimal solutions. Cardiology. 2016; 56(8): 46-53. [In Russian]; Бокерия О.Л., Ахобеков А.А., Шварц В.А., Глушко Л.А., Ле Т.Г. Метаанализ клинических исследований по применению статинов в профилактике фибрилляции предсердий в ранние сроки после аортокоронарного шунтирования. Клин. мед. 2016; 94 (2): 85-92. DOI:10.18821/0023-2149-2016-94-2-85-92. Bokeriya OL, Akhobekov AA, Shvarts VA. et al. Meta-analysis of clinical studies on the use of statins for atrial fibrillation soon after coronary bypass surgery. Le TG. Klin. Med. (Mosk). 2016; 94(2): 85-92. DOI:10.18821/0023-2149-2016-94-2-85-92. [In Russian]; Mangieri A. Renin-angiotensin system blockers in cardiac surgery. J. Crit. Care. 2015; 30(3): 613-618.; Martino A., Pezzi L., Magnano R. et al. Omega 3 and atrial fibrillation: Where are we? World J. Cardiol. 2016; 8(2): 114-119. DOI:10.4330/wjc.v8.i2.114.; Yang Q., Qi X., Li Y. The preventive effect of atorvastatin on atrial fibrillation: a meta-analysis of randomized controlled trials. BMC Cardiovasc. Disord. 2014; 14: 90-99.; Шевелёк А.Н. Фибрилляция предсердий: предикторы развития рецидивов и медикаментозная профилактика. Донецк.: Каштан 2015; 164 с. Shevelok A.N. Atrial fibrillation: predictors of recurrence and drug prevention. Donetsk.: Kashtan 2015; 164. [In Russian]; Pedersen O.D., Bagger H., Kober L. et al. Trandopril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction. Circulation. 1999; 100: 376-380.; Vermes E., Tardif J.C., Bourassa M.G. et al. Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation. 2003; 107: 2926-2931.; Maggioni A.P., Latini R., Carson P.E. et al. Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: results from the Valsartan Heart Failure Trial (Val-HeFT). Am. Heart J. 2005; 149: 548-57.; Wachtell K., Lehto M., Gerdts E. et. al. Angiotensin-II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J. Am. Coll. Cardiol. 2005; 45: 712-719.; Schmieder R.E., Kjeldsen S.E., Julius S. et al. VALUE Trial Group Reduced incidence of new-onset atrial fibrillation with angiotensin II receptor blockade: the VALUE trial. J. Hypertens. 2008; 26: 403-411.; Disertori M., Latini R., Barlera S. et al. Valsartan for prevention of recurrent atrial fibrillation. N. Engl. J. Med. 2009; 360 (16): 1606-1617. DOI:10.1056/NEJMoa0805710.; Yamashita T., Inoue H., Okumura K. et al. Randomized trial of angiotensin II-receptor blocker vs. dihydropiridine calcium channel blocker in the treatment of paroxysmal atrial fibrillation with hypertension (J-RHYTHM II study). J-RHYTHM II Investigators. Europace 2011; 13 (4): 473-479.; Goette A., Breithardt G., Fetsch T. et al. Angiotensin II antagonist in Paroxismal Atrial Fibrillation (ANTIPAF) trial: rationale and study design. Clin. Drug Investig. 2007; 27 (10): 697-705.; Murray K.T., Rottman J.N., Arbogast P.G. et al. Inhibition of angiotensin II signaling and recurrence of atrial fibrillation in AFFIRM. Heart Rhythm. 2004; 1 (6): 669-675.; Reil J.C., Hohl M., Selejan S. et al. Aldosterone promotes atrial fibrillation. Europ. Heart J. 2012; 33: 2098–2108.; Lavall D., Selzer C., Schuster P. et al. The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation. Biol. Chem. 2014; 289 (10): 6656-6668.; Yang S.S., Han W., Zhou H.Y. et al. Effects of spironolactone on electrical and structural remodeling of atrium in congestive heart failure dogs. Chin. Med. J. (Engl). 2008; 121: 38-42.; Lammers C., Dartsch T., Brandt M.C. et al. Spironolactone prevents aldosterone induced increased duration of atrial fibrillation in rat. Cell Physiol. Biochem. 2012; 29 (5-6): 833-840.; Zhao Y., Yuan Y., Qiu C. Underexpression of CACNA1C caused by overexpression of microRNA-29a underlies the pathogenesis of atrial fibrillation. Med. Sci. Monit. 2016; 22: 2175-2181.; Takemoto Y., Ramirez R.J., Kaur K. et al. Eplerenone reduces atrial fibrillation burden without preventing atrial electrical remodeling. J. Am. Coll. Cardiol. 2017; 70(23): 2893-2905.; Du L., Qin M., Yi Y. et al. Eplerenone prevents atrial fibrosis via the TGF-β signaling pathway. Cardiology. 2017; 138(1): 55-62.; Stein M., Boulaksil M., Jansen J.A. et al. Reduction of fibrosis-related arrhythmias by chronic renin-angiotensin-aldosterone system inhibitors in an aged mouse model. Am. J. Physiol. Heart Circ. Physiol. 2010; 299 (2): 310-321.; Muñoz-Durango N., Vecchiola A., Gonzalez-Gomez L.M. et al. Modulation of Immunity and Inflammation by the Mineralocorticoid Receptor and Aldosterone. BioMed Research International. 2015; 11: 134-139.; DeVore A.D., Piccini J.P. Mineralocorticoid receptor antagonism for the treatment of AF and HFpEF: preserving hope. JACC Heart Fail. 2018; 6(8): 698-700.; Минушкина Л.О., Затейщиков Д.А. Эплеренон — селективный блокатор рецепторов альдостерона. Фарматека. 2007; 3: 10-17. Minushkina L.O., Zateeyshikov D.A. Eplerenone is a selective blocker of aldosterone receptors. Pharmateka. 2007; 3: 10-17. [In Russian]; Swedberg K., Zannad F., McMurray J.J. et al. Eplerenone and atrial fibrillation in mild systolic heart failure: results from the EMPHASISHF (Eplerenone in Mild Patients Hospitalization And SurvIval Study in Heart Failure) study/ J. Am. Coll. Cardiol. 2012; 59: 1598-1603.; Rossi G.P., Seccia T.M., Gallina V. et al. Prospective appraisal of the prevalence of primary aldosteronism in hypertensive patients presenting with atrial flutter or fibrillation (PAPPHY Study): rationale and study design. J. Hum. Hypertens 2013; 27 (3): 158-163.; Ito Y., Yamasaki H., Naruse Y. et al. Effect of eplerenone on maintenance of sinus rhythm after catheter ablation in patients with long-standing persistent atrial fibrillation. Am. J. Cardiol. 2013; 111 (7): 1012-1018.; Dabrowski R., Borowiec A., Smolis-Bak E. et al. Effect of combined spironolactone-β-blocker ± enalapril treatment on occurrence of symptomatic atrial fibrillation episodes in patients with a history of paroxysmal atrial fibrillation (SPIR-AF study). Am. J. Cardiol. 2010; 106 (11): 1609-1614.; Gao X., Peng L., Adhikari C.M. et al. Spironolactone reduced arrhythmia and maintained magnesium homeostasis in patients with congestive heart failure. J. Card. Fail. 2007; 13: 170-177.; Pretorius M., Murray K.T. et al. Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery. Crit. Care Med. 2012; 40 (10): 2805-2812.; Ватутин Н.Т., Кравченко И.Н. Влияние антагонистов минералокортикоидных рецепторов на электрофизиологические параметры миокарда у пациентов с рецидивирующей фибрилляцией предсердий и диастолической дисфункцией левого желудочка. Медицинский вестник Юга России 2016; 3: 41-47. Vatutin N.T., Kravchenko I.N. Effect of mineralocorticoid receptor antagonists on electrophysiological parameters of the myocardium in patients with recurrent atrial fibrillation and diastolic left ventricular dysfunction. Medical Gazette of the South of Russia. 2016; 3: 41-47. [In Russian]; Mattias J., Ling J., Smith T. et al. Inhibition of Aldosterone to Reduce Myocardial Diffuse Fibrosis in Patients with Paroxysmal and Persistent Atrial Fibrillation in Preventing Recurrent Episodes of Atrial Fibrillation (INSPIRE-AF). JAMA 2015; 467: 1520-1524.; Shantsila E., Haynes R., et al. Improved exercise tolerance in patients with PReserved Ejection fraction by Spironolactone on myocardial fibrosiS in Atrial Fibrillation rationale and design of the IMPRESS-AF randomised controlled trial. B. M. J. Open. 2016; 6 (10): P. e012241.; https://www.medarhive.ru/jour/article/view/946Test

الإتاحة: https://doi.org/10.20514/2226-6704-2019-9-4-260-268Test
https://doi.org/10.20514/2226-6704-2019-9-4Test
https://doi.org/10.1016/jTest
https://doi.org/10.1210/en.2016-1375Test
https://doi.org/10.1016/j.suc.2014.02.007Test
https://doi.org/10.1161/CIRCRESAHA.116.303587Test
https://doi.org/10.1111/jvp.12154Test
https://doi.org/10.18821/0023-2149-2016-94-2-85-92Test
https://doi.org/10.1056/NEJMoa0805710Test
https://www.medarhive.ru/jour/article/view/946Test

View record in BASE

10

دورية أكاديمية

CASE OF ACQUIRED COAGULOPATHY ; СЛУЧАЙ ПРИОБРЕТЕННОЙ КОАГУЛОПАТИИ

المؤلفون: M. T. Vatutin, E. S. Gasendich, E. I. Iofe, Н. Т. Ватутин, Е. С. Гасендич, Е. И. Иофе

المصدر: The Russian Archives of Internal Medicine; Том 8, № 6 (2018); 480-482 ; Архивъ внутренней медицины; Том 8, № 6 (2018); 480-482 ; 2411-6564 ; 2226-6704 ; 10.20514/2226-6704-2017-0-4-5

مصطلحات موضوعية: когнитивные нарушения, acquired coagulopathy, cognitive impairment, приобретенные коагулопатии

وصف الملف: application/pdf

العلاقة: https://www.medarhive.ru/jour/article/view/859/743Test; https://www.medarhive.ru/jour/article/view/859/755Test; Дземешкевич С.Л., Панченко Е.П. Антикоагулянтная терапия у пациентов с клапанными пороками сердца. Русский медицинский журнал. 2001; 10: 427.; Кропачева Е.С., Панченко Е.П. Практические аспекты терапии варфарином. Медицина неотложных состояний. 2007; 1(8): 37-42.; Кудряшова Б.А. Лечение оральными антикоагулянтами. Рекомендации Всероссийской ассоциации по изучению тромбозов, геморрагий и патологии сосудов имени А. Шмидта. М.: РКИ, Соверо пресс. 2004; 40 c.; Метелица В.И. Справочник по клинической фармакологии сердечно-сосудистых лекарственных средств. 2-е изд. М.: БИНОМ. СПб.: Невский Диалект. 2002; 926 с.; Chakraverty R., Davidson S., Peggs K. et al. The incidence and cause of coagulopathies in an intensive care population. Br. J. Haematol. 1996; 93: 460-463.; Deloughery T.G. Hemorrhagic and Thrombotic Disorders in the Intensive Care Setting. In: Kitchens C.S., ed. Consultative Hemostasis and Thrombosis. W.B.: Saunders Company. 2004: 493-514.; Hylek E.M., Chang Y.C., Skates S.J. et al. Prospective study of the outcomes of ambulatory patients with excessive warfarin anticoagulation. Arch. Intern. Med. 2000; 160: 1612-1617.; Dagres N., Chao T.F., Fenelon G. et al. Arrhythmias and cognitive function. Eur Heart J. 2018; 39(26): 2446–2447.; https://www.medarhive.ru/jour/article/view/859Test

الإتاحة: https://doi.org/10.20514/2226-6704-2018-8-6-480-482Test
https://doi.org/10.20514/2226-6704-2017-0-4-5Test
https://www.medarhive.ru/jour/article/view/859Test

View record in BASE

تنقيح النتائج